Clinical profile and treatment outcomes in antisynthetase syndrome: a tertiary centre experience.
anti-Jo-1
antisynthetase
interstitial lung disease
myositis
seronegative arthritis
Journal
Rheumatology advances in practice
ISSN: 2514-1775
Titre abrégé: Rheumatol Adv Pract
Pays: England
ID NLM: 101736676
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
14
04
2021
accepted:
18
05
2021
entrez:
10
11
2021
pubmed:
11
11
2021
medline:
11
11
2021
Statut:
epublish
Résumé
The aim was to describe the clinical profile and outcomes in patients with antisynthetase syndrome (ASS) from a tertiary care centre. The clinical data and investigations of all patients classified as ASS by Connors criteria over 5 years were recorded, and they were followed up prospectively. The median (interquartile range) was used for descriptive statistics. Clinical variables between the Jo-1 and non-Jo-1 groups and between patients with and without anti-Ro52 antibodies were compared using the χ The 28 patients (23 females) had a median age of 42.5 (34.8-52.3) years, with a disease duration of 1.75 (0.6-3.8) years at diagnosis, and had a follow-up of 2 (0.25-4.25) years. Seronegative arthritis was seen in 23 of 28 patients. Non-specific interstitial pneumonia was seen in 19 patients with interstitial lung disease (ILD). Antibodies to Jo-1 ( The most typical presenting manifestation of ASS in our cohort was isolated seronegative arthritis. Non-specific interstitial pneumonia was the commonest ILD pattern. Patients with antibodies to Jo-1 had better survival compared with non-Jo-1. The non-Jo-1 aminoacyl-transfer RNA synthetases had a strong association with anti-Ro52 antibodies.
Identifiants
pubmed: 34755025
doi: 10.1093/rap/rkab054
pii: rkab054
pmc: PMC8570161
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ii10-ii18Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Références
ISRN Rheumatol. 2012;2012:415272
pubmed: 22567412
Ann Rheum Dis. 2019 Jun;78(6):858-860
pubmed: 30760469
Rheumatology (Oxford). 2017 Jun 1;56(6):999-1007
pubmed: 28339994
Clin Rheumatol. 2015 Sep;34(9):1563-9
pubmed: 26219488
Autoimmun Rev. 2012 Aug;11(10):739-45
pubmed: 22326685
Medicine (Baltimore). 2015 Aug;94(32):e1144
pubmed: 26266346
Clin Rev Allergy Immunol. 2017 Feb;52(1):1-19
pubmed: 26424665
J Rheumatol. 2017 Jul;44(7):1051-1057
pubmed: 28461650
Chest. 2010 Dec;138(6):1464-74
pubmed: 21138882
Rheumatology (Oxford). 2015 May;54(5):927-32
pubmed: 25349440
Clin Exp Rheumatol. 2018 Jan-Feb;36(1):44-49
pubmed: 28770709
Ann Rheum Dis. 2014 Jan;73(1):227-32
pubmed: 23422076
Rheumatology (Oxford). 2010 Dec;49(12):2370-4
pubmed: 20724434
Autoimmun Rev. 2012 Dec;12(2):210-7
pubmed: 22771754
Ann Rheum Dis. 2009 Jan;68(1):152-3
pubmed: 19088260
Lung India. 2016 Jan-Feb;33(1):20-6
pubmed: 26933302
Arthritis Rheum. 1990 Nov;33(11):1640-5
pubmed: 2242062
J Clin Rheumatol. 2021 Jun 1;27(4):150-155
pubmed: 31895110
J Rheumatol. 2012 Sep;39(9):1835-9
pubmed: 22859355
Clin Rev Allergy Immunol. 2017 Feb;52(1):71-80
pubmed: 26782036
Semin Arthritis Rheum. 2016 Oct;46(2):225-231
pubmed: 27139168
Rheumatol Int. 2016 Jul;36(7):935-43
pubmed: 27193471
Mod Rheumatol. 2016;26(3):403-9
pubmed: 26344678
Clin Exp Immunol. 1997 Jul;109(1):32-40
pubmed: 9218821